降钙素基因相关肽
偏头痛
安慰剂
医学
降钙素
慢性偏头痛
单克隆抗体
麻醉
药理学
内科学
受体
数据科学
计算机科学
抗体
免疫学
替代医学
神经肽
病理
标识
DOI:10.1016/s1474-4422(22)00489-6
摘要
Drugs targeting the calcitonin gene-related peptide (CGRP) pathway have transformed the management of migraine. Several publications have shown the efficacy of monoclonal antibodies to CGRP or its receptor for prophylaxis of difficult-to-treat migraine. In 2022, this work was complemented by a study of intravenous eptinezumab in patients with 2–4 previous unsuccessful attempts at prophylactic treatment.1 In line with data from studies with erenumab, galcanezumab, and fremanezumab, a single infusion of 100 mg or 300 mg eptinezumab led to a significant reduction in monthly migraine days compared with the placebo group during the 12-week double-blind observation period (difference from placebo –2·7 days [95% CI –3·4 to –2·0] with 100 mg eptinezumab and –3·2 days [–3·9 to –2·5] with 300 mg eptinezumab).
科研通智能强力驱动
Strongly Powered by AbleSci AI